This Week’s Biotech and Cannabis Stocks to Watch
Back to Newsroom
Mentioned in this Article

This Week’s Biotech and Cannabis Stocks to Watch

Wednesday, October 10, 2018 10:30 AM
Share this article now

HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Stocks in the biotech and cannabis industries provide investors the largest gains. That’s why we always have our ear to the ground for the best opportunities in these sectors. Below are several stocks that can make investors huge profits.

One stock we think could bring investors particularly large profits is Endonovo Therapeutics, Inc. (ENDV). This 5 cent stock has received price targets from research firms as high as 25 cents a share.

This company has been making progress for years. While the company is developing their non-invasive Immunotronics treatment for heart failure which has past pre-clinical and has had favorable results; the reason we're excited is about ENDV is they're under the radar SofPulse technology.

The non-invasive pain reduction treatment could render troublesome opioid prescriptions irrelevant. The company just released news that they have secured sales, marketing and distribution.

Biotech and cannabis companies to look at include: Endonovo Therapeutics, Inc. (ENDV), vTv Therapeutics, Inc. (NASDAQ: VTVT), 22nd Century Group Inc. (XXII), Aurora Cannabis, Inc. (ACBFF) and India Globalization Capital, Inc. (NYSE American: IGC).

Endonovo Therapeutics, Inc. (ENDV)

Market Cap: $18.98M Share Price: $0.05

Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, announced a distribution agreement with Magniant, LLC for the distribution of SofPulse®, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.

Alan Collier, Endonovo Chief Executive Officer, stated, "We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our Sofpulse device on a national level."

vTv Therapeutics, Inc. (NASDAQ: VTVT)

Market Cap: $143.33M Share Price: $3.70

VTVT recently reported its second quarter results. The company reported loss of $0.29 per share for the quarter, which trailed behind the consensus estimates of loss per share of $0.25 by $0.04. vTv Therapeutics reported revenue of $2.47 million, while analysts had expected revenue of $2.46 million. It was revealed at the end of last month that major shareholder Ronald O. Perelman had acquired 1,879,699 shares of vTv Therapeutics stock in a transaction on Thursday, September 6th. The company discovers, develops, and sells orally administered small molecule drug candidates worldwide and has a drug candidate called azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

22nd Century Group Inc. (XXII)

Market Cap: $386.25M Share Price: $3.09

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced that the National Institute on Drug Abuse (NIDA), the U.S. Food and Drug Administration (FDA), and public health researchers have requested a new, significant quantity of 22nd Century's proprietary SPECTRUM® research cigarettes. In coordination with NIDA, FDA, and others, RTI International has submitted an order to 22nd Century for 3.6 million SPECTRUM® research cigarettes.

Oragenics, Inc. (NYSE American: OGEN)

Market Cap: $19.92 Share Price: $1.73

Oragenics, Inc. (OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM).

India Globalization Capital, Inc. (NYSE American: IGC)

Market Cap: $182.40M Share Price: $5.47

IGC announced that it has executed a distribution and partnership agreement for several products including a sugar free, energy drink called 'Nitro G'. IGC plans to create a branded, hemp/CBD-infused version of the formulation that addresses market demand for energy drinks with the inclusion of healthy properties derived from hemp including CBD.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seventy-four thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of ENDV in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: [email protected]

Phone: 1-702-720-6310

Country: United States


SOURCE: ACR Communication, LLC

ACR Communication, LLC
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions